Abstract Objective To study the effect of epigallocatechin-3-gallate (EGCG) on liver lipid metabolism in rats with intrauterine growth restriction (IUGR) and related mechanism. Methods A rat model of IUGR was established by food restriction during entire pregnancy, and then the rats were randomly divided into an IUGR group and an EGCG group (n=8 each). The rats in the EGCG group were fed with water containing EGCG from after weaning to 10 weeks. Eight pup rats born from the pregnant maternal rats without food restriction were used as the control group. At the age of 13 weeks, body weight was measured. Blood and liver tissue samples were collected to measure fasting total cholesterol (TC), triglyceride (TG), free fatty acid (FFA), fasting plasma glucose (FPG), fasting insulin (FINS), and liver lipids. Homeostasis model assessment of insulin resistance (HOMA-IR) and adipose insulin resistance (adipo-IR) were calculated. Pathological sections of the liver were observed and quantitative real-time PCR was used to measure the mRNA expression of related genes in the liver. Results At the age of 13 weeks, there was no significant difference in body weight between groups (P=0.067). There were significant differences between groups in FPG, FFA, FINS, HOMA-IR, and adipo-IR (P P > 0.05), while the IUGR group had significantly higher levels of TC and TG in the liver than the EGCG group (P P P > 0.05). Conclusions Early EGCG intervention can down-regulate the de novo synthesis of fatty acids through the Ampk/Srebf1 signaling pathway and reduce hepatic lipid accumulation in IUGR rats by improving insulin resistance of hepatocytes.
CHEN Lian-Hui,WU Min,HU Xiao-Hao et al. Effect of epigallocatechin-3-gallate on liver lipid metabolism in rats with intrauterine growth restriction and related mechanism[J]. CJCP, 2020, 22(1): 65-70.
CHEN Lian-Hui,WU Min,HU Xiao-Hao et al. Effect of epigallocatechin-3-gallate on liver lipid metabolism in rats with intrauterine growth restriction and related mechanism[J]. CJCP, 2020, 22(1): 65-70.
Chen C, Liu Q, Liu L, et al. Potential biological effects of (-)-epigallocatechin-3-gallate on the treatment of nonalcoholic fatty liver disease[J]. Mol Nutr Food Res, 2018, 62(1). doi:10.1002/mnfr.201700483. Epub 2017 Oct 12.
[5]
Shimano H, Sato R. SREBP-regulated lipid metabolism:convergent physiology-divergent pathophysiology[J]. Nat Rev Endocrinol, 2017, 13(12):710-730.
[6]
Enjoji M, Yasutake K, Kohjima M, et al. Nutrition and nonalcoholic fatty liver disease:the significance of cholesterol[J]. Int J Hepatol, 2012, 2012:925807.
[7]
Garofano A, Czernichow P, Bréant B. In utero undernutrition impairs rat beta-cell development[J]. Diabetologia, 1997, 40(10):1231-1234.
[8]
Schwitzgebel VM, Somm E, Klee P. Modeling intrauterine growth retardation in rodents:impact on pancreas development and glucose homeostasis[J]. Mol Cell Endocrinol, 2009, 304(1-2):78-83.
[9]
Kayemba-Kay's S, Maillet O, Hindmarsh P, et al. Growth screening in children aged 3-5 years:a useful tool for public health programs in community pediatrics[J]. J Pediatr Endocrinol Metab, 2019, 32(7):727-732.
[10]
Niu Y, He J, Ahmad H, et al. Curcumin attenuates insulin resistance and hepatic lipid accumulation in a rat model of intrauterine growth restriction through insulin signaling pathway and sterol regulatory element binding proteins[J]. Br J Nutr, 2019, 122(6):616-624.
[11]
Smith BK, Steinberg GR. AMP-activated protein kinase, fatty acid metabolism, and insulin sensitivity[J]. Curr Opin Clin Nutr Metab Care, 2017, 20(4):248-253.
[12]
Day EA, Ford RJ, Steinberg GR. AMPK as a therapeutic target for treating metabolic diseases[J]. Trends Endocrinol Metab, 2017, 28(8):545-560.
[13]
Yang CS, Zhang J, Zhang L, et al. Mechanisms of body weight reduction and metabolic syndrome alleviation by tea[J]. Mol Nutr Food Res, 2016, 60(1):160-174.
[14]
Li F, Gao C, Yan P, et al. EGCG reduces obesity and white adipose tissue gain partly through AMPK activation in mice[J]. Front Pharmacol, 2018, 9:1366.
[15]
Song Z, Xiaoli AM, Yang F. Regulation and metabolic significance of de novo lipogenesis in adipose tissues[J]. Nutrients, 2018, 10(10). pii:E1383.
[16]
Moslehi A, Hamidi-zad Z. Role of SREBPs in liver diseases:amini-review[J]. J Clin Transl Hepatol, 2018, 6(3):1-7.
[17]
Ferenc K, Pietrzak P, Wierzbicka M, et al. Alterations in the liver of intrauterine growth retarded piglets may predispose to development of insulin resistance and obesity in later life[J]. J Physiol Pharmacol, 2018, 69(2):211-218.
